Ana Luisa Perdigoto, MD, PhD
Assistant Professor of Medicine (Endocrinology)Cards
About
Research
Publications
2026
Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations
Herold K, Perdigoto A. Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations. Journal Of Clinical Investigation 2026, 136: e202477. PMID: 41697752, PMCID: PMC12904721, DOI: 10.1172/jci202477.Peer-Reviewed Original ResearchAnti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes
Wu Y, Spurrell M, Lledó-Delgado A, Deng S, Wang D, Liu Y, Barkestani M, Perdigoto A, Herold K. Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes. JCI Insight 2026, 11: e192755. PMID: 41574610, PMCID: PMC12892913, DOI: 10.1172/jci.insight.192755.Peer-Reviewed Original Research
2025
Towards insulin independence in type 1 diabetes: Prospects for prevention and cure
Sydney G, Perdigoto A, Herold K. Towards insulin independence in type 1 diabetes: Prospects for prevention and cure. PLOS Medicine 2025, 22: e1004813. PMID: 41289263, PMCID: PMC12646415, DOI: 10.1371/journal.pmed.1004813.Peer-Reviewed Original ResearchImmune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients
Gaiger N, Hurwitz M, Hafez N, Kluger H, Herold K, Perdigoto A. Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients. Frontiers In Endocrinology 2025, 16: 1697724. PMID: 41282287, PMCID: PMC12634352, DOI: 10.3389/fendo.2025.1697724.Peer-Reviewed Original ResearchConsensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
Zhu L, Cheung Y, Chiang C, Gallagher E, Hamnvik O, Mammen J, Quandt Z, Jones R, McDunn J, Al-Bahadili H, Angell T, Bancos I, Warner A, Blackwell S, Calabrese C, Cho T, Dougan M, Ferreira M, Funchain P, Herndon J, Johnson D, Kennedy R, Kheterpal M, Khouri M, Lechner M, Lim A, Markova A, Meara A, Overton L, Perdigoto A, Sachithanandan N, Sharon E, Spain L, Tsai K, Yarchoan M, Reynolds K, Shariff A. Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors. Journal For ImmunoTherapy Of Cancer 2025, 13: e011865. PMID: 41093625, PMCID: PMC12530408, DOI: 10.1136/jitc-2025-011865.Peer-Reviewed Original ResearchCTLA-4 blockade shifts the B cell repertoire towards autoimmunity
Çakan E, Wang M, Dai Y, Mirouse A, Villanueva-Pachas C, Bouis D, Boeckers J, Gera R, Yraita S, Clapp L, Perdigoto A, Delmotte F, Massad C, Bacchiocchi A, Ring A, Kluger Y, Kluger H, Herold K, Meffre E. CTLA-4 blockade shifts the B cell repertoire towards autoimmunity. Journal Of Clinical Investigation 2025, 135: e189074. PMID: 41026527, PMCID: PMC12618075, DOI: 10.1172/jci189074.Peer-Reviewed Original ResearchFactors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes
Aizenbud L, Gaiger N, Perdigoto A, Mann J, Torres M, Boland G, Lawless A, Silverman S, Schoenfeld D, Destina J, Hasson N, Tran T, Hurwitz M, Austin M, Sullivan R, Herold K, Kluger H. Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes. Journal For ImmunoTherapy Of Cancer 2025, 13: e012358. PMID: 40935567, PMCID: PMC13059913, DOI: 10.1136/jitc-2025-012358.Peer-Reviewed Original ResearchAutoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas
Quandt Z, Young A, Barlow G, Smith J, Kusmartseva I, Dong S, Shapiro M, Kang J, Felton J, Nguyen V, Szot G, Hassoun A, Perdigoto A, Herold K, Nolan G, Bollyky P, Brusko T, Nakayama M, Cooper S, Anderson M. Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas. Journal For ImmunoTherapy Of Cancer 2025, 13: e011818. PMID: 40813111, PMCID: PMC12359507, DOI: 10.1136/jitc-2025-011818.Peer-Reviewed Original Research
2024
Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease
Quandt Z, Perdigoto A, Anderson M, Herold K. Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harbor Perspectives In Medicine 2024, 15: a041603. PMID: 39038853, PMCID: PMC11917379, DOI: 10.1101/cshperspect.a041603.Peer-Reviewed Original ResearchThe immunology of type 1 diabetes
Herold K, Delong T, Perdigoto A, Biru N, Brusko T, Walker L. The immunology of type 1 diabetes. Nature Reviews Immunology 2024, 24: 435-451. PMID: 38308004, PMCID: PMC7616056, DOI: 10.1038/s41577-023-00985-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
Academic Achievements & Community Involvement
News
News
- July 01, 2025
How Immune Checkpoint Inhibitors Can Induce Diabetes
- January 06, 2025
Request for Nominations: 2025 Iva Dostanic Award
- August 01, 2024
Meet Yale Internal Medicine: Ana Luisa Perdigoto, MD, PhD
- June 05, 2023
Discoveries & Impact (June 2023)